
FIG. 1



DLT- dose limiting toxicity, DR- dose reduction

FIG. 2



AZD9833: Days on Study Drug and Response
Duration of Exposure (Days)
0
25
50
75
100
125
150
175
200
225
250
275
300
325
350
375
400
Treatment Ongoing
Death
1 2 3 4
25mg (N=12)
75mg (N=12)
150mg (N=13)
PR
SD
PD

FIG. 2
(continuation)




FIG. 3




Dose (mg)
25
75
150
300
450
Best Change from Baseline %
100
80
60
40
20
0
-20
-40
-60
-80
-100
▲=Value over 100%
Prior Fulvestrant
Prior CDK4/6
Prior Chemotherapy
ESR1 Mutation
Liver disease
BL tumour >=5cm

FIG. 4


D8530C00001 Mean Plasma AZD9833 PK Time Course monotherapy
Day 1-Cycle 1
Mean (SD) Plasma AZD9833 Concentration (ng/ml) monotherapy
1,000
100
10
0 1 2 4 6 8 10 24
Time Post-Dose [hours]
25 mg
75 mg
150 mg
300 mg
450 mg